MONTREAL, QUEBEC--(MARKET WIRE)--May 9, 2008 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News) announced today that it will be hosting a conference call and webcast on Wednesday, May 14, 2008, at 9:00 am ET, to discuss the financial results for the first quarter ended March 31, 2008, and provide an update on the strategy execution. Prior to the conference call, a press release will be issued on Wednesday, May 14, 2008, at approximately 8:00 am ET. The call will be hosted by Dr. Philippe Calais, President and Chief Executive Officer and Ms. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer.

Interested parties may access the conference call by way of telephone or webcast. The numbers to access the conference call are 416 644 3426 (international) and 1 800 590 1508 (toll free). The webcast will be available on the Company's website at www.ambrilia.com, Investors' section, Conference calls and webcasts, and will be archived for 365 days.

A replay of the call will be available on the Company's website at www.ambrilia.com, Investors' section, Conference calls and webcasts, from Wednesday, May 14, 2008, 11:00 am ET to Wednesday, May 21, 2008, 11:59 pm ET, and the numbers to access the replay are 416 640 1917 (international) and 1 877 289 8525 (toll free) with access code 21271117.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (Toronto:AMB.TO - News) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. In the latter part of 2007, Ambrilia adopted a new strategic plan, the primary objective of which is to progressively refocus R&D activities solely on antivirals. The strategy aims to capitalize on the Company's broad portfolio and original expertise in virology. Today, Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, a HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.), HIV integrase inhibitor and entry inhibitor programs, and a HCV polymerase inhibitor program. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

     Contacts:
     Ambrilia Biopharma Inc.
     Julie M. Thibodeau, B.Sc., MBA
     Director, Communications
     514-751-2003 ext 235
     jthibodeau@ambrilia.com / ir@ambrilia.com
     http://www.ambrilia.com